What's Happening

Stay up to date on pharmaceutical developments, industry issues, and what’s happening with Healthesystems

Events

Healthesystems’ conferences and speaking engagements

National Comp (NWCD Conference)

October 20-21, 2021   Las Vegas, NV

Visit Healthe in booth #830 to participate in our Annual Industry Survey for a chance to win $500.

Attend our VP of Clinical Services, Dr. Silvia Sacalis’ session on Wed 10/20 @ 11:00 Am: “The New Rules of Infectious Disease Post-Pandemic: Adapt, Be Ready, Be Resilient”

WCI Annual Conference

December 12-15, 2021   Orlando, FL

Visit Healthe in the exhibit hall to learn more about our workers’ comp pharmacy & ancillary benefits solutions.

MedMonitor

An up-to-date timeline of FDA approvals that could impact workers' comp
View All MedMonitor Information

Loreev XR (lorazepam) extended release capsules

Approval Date: Sep 2021

Note: New Product

For the treatment of anxiety disorders in adults receiving stable, evenly divided, three times daily dosing with lorazepam tablets

hello world!

Januvia® (sitagliptin) tablets

Approval Date: Sep 2021

Note: New Product

A once-daily medication indicated to help lower blood sugar with type 2 diabetes, in conjunction with diet and exercise

hello world!

Trudhesa (dihydroergotamine mesylate) nasal spray

Approval Date: Sep 2021

Note: New Product

Indicated for the acute treatment of migraine with or without aura

hello world!

Qulipta (atogepant) tablets for oral use

Approval Date: Sep 2021

Note: New Product

Indicated for the preventive treatment of episodic migraine

hello world!

Xeljanz® XR (tofacitnib) extended-release tablets

Approval Date: Aug 2021

Note: First-Time Generic

This is the first time a generic has been approved for Xeljanz XR – other formulations of Xeljanz have received generic approvals, but this new generic approval applies to the extended-release formulation. For the treatment of moderate-to-severe active rheumatoid arthritis, active psoriatic arthritis, or ulcerative colitis

hello world!

Duexis® (ibuprofen and famotidine) tablets

Approval Date: Aug 2021

Note: First-Time Generic

This is the first time a generic has been approved for Duexis. For the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, and to decrease the risk of developing upper gastrointestinal ulcers

hello world!

Belbuca® (buprenorphine) buccal film

Approval Date: Aug 2021

Note: First-Time Generic

This is the first time a generic has been approved for Belbuca. For the management of pain severe enough to require daily, around the clock, long-term opioid treatment for which alternative treatment options are inadequate

hello world!

Semglee® (insulin glargine-yfgn) injection for subcutaneous use

Approval Date: Jul 2021

Note: New Product

This is the first time a generic has been approved for Semglee. For the treatment of Type 1 and Type 2 diabetes, this drug is both a biosimilar to, and interchangeable with Lantus (insulin glargine)

hello world!

WEGOVY (SEMAGLUTIDE) INJECTION

Approval Date: Jun 2021

Note: New Product

For chronic weight management with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol) for use in addition to a reduced calorie diet and increased physical activity

hello world!

ADUHELM (ADUCANUMAB-AVWA) INJECTION

Approval Date: Jun 2021

Note: New Product

A first-of-its-kind, biologic treatment for Alzheimer’s disease. This drug is the first new Alzheimer’s drug since 2003

hello world!
1 2 3

Social Hub

Check out our latest posts and activity
View All Social Media
    lockenvelopephone-handsetmenucross-circle